Dawn Ayers, MD
Endocrinology, Diabetes & Metabolism · Zionsville, INNPI 1306823513
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,850 of the $46,739 with a category attached, or 66.0%. 56 manufacturers reported payments, led by AbbVie at 40.1% of the total. Reporting peaked in 2019 at $28,840 and has fallen 93.0% since, to $2,030 in 2025.
Across 800 payments — averaging $58.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$19K
- Johnson & Johnson$14K
- Sanofi-aventis U.S. LLC$3K
- AstraZeneca$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- plus $7K from 50 others
What the payments were for
- Consulting fees$2,0904%
- Speaking & faculty fees$30,85066%
- Travel & lodging$1,1212%
- Food & beverage$12,64227%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synthroid$16,813
- INVOKANA$14,054
- DISEASE STATE$2,090
- FARXIGA$131
How this compares
$46,739 in reported general payments places this provider in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 186 | $305,475 |
| Signifor LarPasireotide Pamoate | 12 | $223,264 |
| OzempicSemaglutide | 180 | $222,749 |
| JardianceEmpagliflozin | 85 | $129,788 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 122 | $121,020 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $69,857 |
| RybelsusSemaglutide | 29 | $63,669 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $57,078 |
| TrulicityDulaglutide | 27 | $50,419 |
| FarxigaDapagliflozin Propanediol | 36 | $41,448 |
| JanuviaSitagliptin Phosphate | 35 | $40,999 |
| SynthroidLevothyroxine Sodium | 335 | $35,487 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $28,677 |
| FiaspInsulin Aspart (Niacinamide) | 21 | $27,531 |
| HumalogInsulin Lispro | 99 | $26,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,130 | $384,140330 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $1,353 | $322,128260 claims |
| Recordati_rare_diseases_inc.Signifor Lar | $94 | $223,26412 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $642 | $151,184113 claims |
| AstraZenecaFarxiga | $1,401 | $41,44836 claims |
| MerckJanuvia | $121 | $40,99935 claims |
| AbbVieSynthroid, Armour Thyroid | $18,753 | $36,864349 claims |
| BayerKerendia | $497 | $21,77015 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $218 | $4,666352 claims |
| Sanofi-aventis U.S. LLCLantus | $2,831 | $1,51712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Zionsville
- Shahab ZaidiZionsville$3K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.